• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Table 30Severity of alanine aminotransferase elevations in beta interferon-treated patients159

InterventionDosageMean durationMean de novo ALT elevation
≥Grade 1≥Grade 2≥Grade 3
Interferon β-1a IM (Avonex®)30 ug 1x/week14.7 months23. 0%1.9%0.0%
Interferon β-1a SC (Rebif®)22 ug 3x/week15.7 months33.6%4.7%1.6%
44 ug 3x/week38.0%7.8%1.6%
Interferon β-1b SC (Betaseron®)250 ug every other day29.5 months38.9%4.3%1.1%

Abbreviations: ALT, alanine aminotransferase; IM, intramuscular; SC, subcutaneous.

From: Results

Cover of Drug Class Review: Disease-modifying Drugs for Multiple Sclerosis
Drug Class Review: Disease-modifying Drugs for Multiple Sclerosis: Final Update 1 Report [Internet].
Smith B, Carson S, Fu R, et al.
Portland (OR): Oregon Health & Science University; 2010 Aug.
Copyright © 2010 by Oregon Health & Science University, Portland, Oregon 97239. All rights reserved.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.